Stable antibody expression at therapeutic levels using the 2A peptide

Jianmin Fang(Genesys (United States)), Jingjing Qian(Genesys (United States)), Saili Yi(Genesys (United States)), Thomas C. Harding(Genesys (United States)), Guang Huan Tu(Genesys (United States)), Melinda VanRoey(Genesys (United States)), Karin Jooss(Genesys (United States))

Nature Biotechnology

April 17, 2005

10.1038/nbt1087

Cited by 384

Abstract

Related Papers

Efficient selection for high-expression transfectants with a novel eukaryotic vector

Hitoshi Niwa, Ken‐ichi Yamamura, Jun‐ichi Miyazaki|Gene|1991|5.2k

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al.|Blood|1997|1.7k

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

Guangping Gao, Mauricio R. Alvira, Lili Wang et al.|Proceedings of the National Academy of Sciences|2002|1.5k

Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

Marie Prewett, JC Huber, Yiwen Li et al.|PubMed|1999|660

IRES-Dependent Second Gene Expression Is Significantly Lower Than Cap-Dependent First Gene Expression in a Bicistronic Vector

Hiroyuki Mizuguchi, Zhili Xu, Akiko Ishii‐Watabe et al.|Molecular Therapy|2000|560